← Back to Search

Monoclonal Antibodies

ZL-1201 for Cancer

Phase 1

Waitlist Available

Research Sponsored by Zai Lab (Shanghai) Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 days after last dose

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions

Advanced Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the time of informed consent to 30 days after last dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the time of informed consent to 30 days after last dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of informed consent to 30 days after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events

Secondary outcome measures

Immunogenicity

Overall Response Rate (ORR）

Pharmacokinetics: CL

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single arm, ZL-1201Experimental Treatment1 Intervention

Single arm, ZL-1201

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ZL-1201

2020

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Zai Lab (Shanghai) Co., Ltd.Lead Sponsor

28 Previous Clinical Trials

3,644 Total Patients Enrolled

Study PhysicianStudy DirectorZai Laboratory

7 Previous Clinical Trials

2,611 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has ZL-1201 been given the green light from the FDA?

"A score of 1 was assigned to ZL-1201's safety due the limited clinical evidence currently available as this is an early phase one trial."

Answered by AI

In how many disparate sites is this experiment being conducted?

"This trial is enlisting participants at US2004 in Phoenix, AZ; US2005 in Jacksonville, FL; and US2001 in Rochester MN as well as five additional sites."

Answered by AI

Are there any current opportunities for volunteers to participate in this trial?

"Clinicaltrials.gov indicates that this medical trial is not currently recruiting patients, though it was first posted on May 11th 2020 and last updated August 25th 2022. Nevertheless, there are still 2,468 other trials actively seeking participants right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Trial of ZL-1201 in Subjects With Advanced Cancer

2020. "A Trial of ZL-1201 in Subjects With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04257617.